12月16日，YOUMAGIC舒立缇及其研发公司威脉医疗联合首科医谷、Med-Inn医学转化驿站(天坛医院) 共同举办的"首科医创汇·医工转化沙龙"在北京成功召开。沙龙汇聚国内顶尖专家学者，聚焦"能量源技 术在皮肤科领域的应用"，围绕医工转化前沿实践，能量源技术的临床应用以及医工转化生态体系的构 建等展开系统研讨。深化全产业链在皮肤治疗领域的医工协同布局，推动医疗产业高质量发展。 医工转化是打通科技创新及应用"最后一公里"的核心路径。清华大学工程物理系李荐民教授在会上系统 分享了清华工物系在能量源技术领域的医工转化实践。表示学科交叉融合是医工转化的核心驱动力，清 华大学工程物理系汇聚了机械、化学、电子、物理等多元学科力量，为医疗技术创新提供了独特优势。 自1956年成立以来，始终以国家重大战略需求为指引，推动尖端技术向产业应用落地。 工物系自1972年起便深耕加速器与能量源等技术，在直线加速器、太赫兹能量源等领域取得世界级突 破。后续逐步推进射频等能量源等技术在医疗领域的转化，已合作威脉医疗将尖端技术转化为射频闭合 系统、YOUMAGIC舒立缇射频皮肤治疗仪、太赫兹生物效应试验系统等多类产品。双方协同打通"选 ...

新华财经上海12月7日电（记者杜康）中国正在跻身全球医疗器械创新的中心。如今，全球医疗器械 TOP 100的名单中，开始出现越来越多中国企业的身影，且排名多呈上升态势。以创新产品叩开海外中 高端市场，一些国内头部企业的海外利润占比总利润已经过半。 在行业人士看来，医疗器械创新始于临床，终于临床。产业、医院、科研机构之间的密切合作，成为中 国医疗器械领域的"创新密码"。前不久，位于上海浦东的医疗器械明星企业上海英诺伟医疗器械股份有 限公司（以下简称"英诺伟"）与复旦大学附属中山医院共同协作研发的一款消化介入领域的低温等离子 设备正式获批，成为"医工结合"推动医疗器械创新的又一典型案例。据悉，这是目前在全球公开已知范 围内，首个获批应用于消化介入领域的低温等离子设备。 "医疗器械创新活力源于 '临床需求牵引 + 平台支撑 + 全周期协作'的生态体系。医工转化不是简单的'技 术买卖'，而是临床与工程的深度融合共创。"英诺伟董事长严航表示。 从临床痛点到行业前列：低温等离子技术在消化内镜领域实现新突破 "我们这款应用于消化内镜领域的等离子产品，是一个典型的医工交叉案例，也是一个从临床需求起 始，成功完成商业化的案例。 ...

Core Insights - The 2025 Global Healthcare Innovation Summit will be held in Shanghai on November 8, focusing on bridging the gap between clinical needs and industrial applications in the healthcare sector [12][11]. - The summit aims to gather clinical experts from the US, Europe, and China to discuss innovative healthcare solutions and share practical case studies [12][11]. - Key topics will include the transformation of clinical innovations under commercial insurance policies and the development of a collaborative ecosystem for healthcare innovation [12][11]. Group 1: Event Overview - The summit is organized by the Shanghai Biopharmaceutical Technology Industry Promotion Center, with support from major companies like Siemens Healthineers and Boston Scientific [12]. - It will feature discussions on cardiovascular, oncology, and neurodegenerative diseases, showcasing global clinical technologies and innovations [12]. - The event aims to create a dedicated communication platform for clinical innovators, enhancing collaboration and resource sharing [12]. Group 2: Expert Participation - The summit will host renowned experts, including Vivek Y. Reddy from Mount Sinai Hospital and Wang Jianan, a Chinese Academy of Sciences academician [13]. - Keynote speeches and roundtable discussions will cover topics such as next-generation therapies and the integration of innovative clinical pathways [13][14]. - The event will also address the role of policy in driving high-quality development in medical technology [14].

Group 1 - The "2025 Ophthalmic Medical Engineering Transformation Innovation Summit" was held in Hangzhou, focusing on the integration of medical and engineering innovations in the ophthalmic field [1][3] - The summit gathered industry experts and representatives to discuss the latest trends, challenges, and solutions in medical technology transformation, aiming to enhance the industrialization of medical technology achievements [1][2] - The Chinese ophthalmic medical device market has surpassed 200 billion yuan in 2024, with a high dependence on imported high-value consumables, reaching nearly 70% [2] Group 2 - The summit featured two core agendas: "Gathering Strengths and Coexistence" and "Chain Movement and Innovation," focusing on policy guidance and technological innovation in key areas such as ophthalmic technology development and cataract treatment [3] - Significant achievements in medical-engineering transformation were showcased, including the development of a new type of artificial lens and innovative non-invasive cataract treatment devices, supported by national key research projects [3][4] - The establishment of the "Medical-Engineering Integration Innovation Alliance" during the summit marks a new phase for clinical transformation projects in ophthalmology, supported by regulatory, industrial, and clinical collaboration [3][4] Group 3 - The summit emphasized the importance of collaboration between clinical medicine and engineering technology to overcome barriers and enhance the practical application of innovative ideas [4] - The company, Haohai Biological Technology, has developed a comprehensive transformation system covering raw material research, process innovation, clinical validation, and product transformation, aiming to enhance the quality of ophthalmic healthcare [4][5] - Haohai aims to accelerate the domestic production process of high-end technologies and provide comprehensive solutions for eye health, contributing to the "Healthy China 2030" initiative [5] Group 4 - The Shanghai Yangtze River Delta Medical Device Industry Development Promotion Association aims to promote innovation and development in the medical device industry, facilitating collaboration among enterprises, research institutions, and medical organizations [6] - Haohai Biological Technology is a leading company in the ophthalmic field, focusing on the research, development, and production of medical devices and pharmaceuticals using biomedicine and genetic engineering technologies [7] - The company has established a global presence and aims to enhance its competitive edge in the ophthalmic medical device market through innovation and integration of high-quality raw materials [7]

Core Insights - The Hainan Boao Lecheng International Medical Tourism Pilot Zone has achieved significant progress in its special drug and medical device policy, with 476 imported special drugs and devices as of April 30, 2025, including 175 drugs and 301 devices [1] Group 1: Policy Advantages - The Lecheng Pilot Zone has four core policy advantages: special drug and device policy, real-world research policy for drugs and devices, real-world research policy for medical insurance, and special operation policy for public hospitals [1] - The special drug and device policy allows the import and use of new drugs and devices that have not yet been approved in China, enabling patients to access the latest global medical innovations more quickly and conveniently [1] Group 2: Future Plans - The Lecheng Medical Supervision Bureau plans to focus on "medical" as the core and actively serve the introduction of special drugs and devices through a traceability platform, transitioning from passive approval to proactive service [2] - The zone aims to introduce a full range of special drugs and devices related to specific diseases and specialties, creating a comprehensive multidisciplinary center for disease management [2] - The plan includes expanding the entire industrial chain of special drugs and devices through real-world data research and medical-engineering transformation, positioning Lecheng as a new highland for drug and device research and development [2] Group 3: Regulatory Commitment - The special drug and device policy is regarded as Lecheng's "golden signboard," with a commitment to maintaining medical safety, ethical safety, and policy safety [3] - The Lecheng Medical Supervision Bureau will continue to support the application of special drugs and devices and real-world data research while strengthening regulation to ensure medical safety [3]

Group 1 - The signing of a comprehensive cooperation agreement between Zhengzhou Airport and Shenzhen Mindray Biomedical Electronics marks a significant achievement in attracting investment in the biomedicine sector [3][9] - Mindray Medical is a global leader in medical devices, holding a crucial position in life information and support, in vitro diagnostics, and medical imaging [3][5] - Zhengzhou Airport aims to establish the Central Plains Medical Science City, focusing on integrating traditional Chinese and Western medicine, and has attracted numerous high-quality enterprises [5][9] Group 2 - The cooperation will involve creating an innovative medical engineering transformation platform, exploring the establishment of a national high-performance medical device sub-center, and planning a Mindray medical equipment storage center [5][9] - Mindray Medical expresses confidence in investing in Henan due to its strong industrial foundation, large market size, and promising development prospects [7][9] - The collaboration is expected to enhance regional medical service levels and technological innovation capabilities, benefiting both parties through mutual cooperation [9]